Mohammad H. Ghalib

Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors

R. Gollamudi, Mohammad H. Ghalib, Kavita Desai et al. · Investigational New Drugs · 2009 · 150 citations · Full text

Viral Replication, Molecular Virology, Intravenous Administration +8

Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i> -Mutated Colorectal Cancer

Sanjay Goel, Allyson J. Ocean, Ruwan Y. Parakrama et al. · Molecular Cancer Therapeutics · 2020 · 32 citations · Full text

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

Sharad Ghamande, Chia‐Chi Lin, Daniel C. Cho et al. · Investigational New Drugs · 2013 · 25 citations

Therapeutic Drug Monitoring, Medicine, Metronomic Therapy +7

Phase I study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer

Jeffrey M. Vainshtein, Mohammad H. Ghalib, Mayank Kumar et al. · Journal of Clinical Oncology · 2008 · 11 citations

On 01910.Na, Pharmacotherapy, Tumor Biology +18

A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant <i>KRAS-</i>mutant metastatic colorectal cancer (mCRC).

Allyson J. Ocean, Tanios Bekaii‐Saab, Imran Chaudhary et al. · Journal of Clinical Oncology · 2013 · 10 citations

Intravenous Administration, Viral Pathogenesis, Immunology +22